A population of immature myeloid cells in the bone marrow can transfer proteinuric kidney disease from affected to unaffected mice. This new finding highlights a possible central role of bone marrow as the source of the circulating factor(s) that lead to recurrent focal segmental glomerulosclerosis and potentially other kidney diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hahm, E. et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat. Med. 23, 100–106 (2017).
Savin, V. J. et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N. Engl. J. Med. 334, 878–883 (1996).
Gallon, L., Leventhal, J., Skaro, A., Kanwar, Y. & Alvarado, A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N. Engl. J. Med. 366, 1648–1649 (2012).
Fogo, A. B. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat. Rev. Nephrol. 11, 76–87 (2015).
Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952–960 (2011).
Cathelin, D. et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J. Am. Soc. Nephrol. 25, 1662–1668 (2014).
Sinha, A. et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 85, 649–658 (2014).
Meijers, B. et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 85, 636–640 (2014).
Bock, M. E., Price, H. E., Gallon, L. & Langman, C. B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin. J. Am. Soc. Nephrol. 8, 1304–1311 (2013).
Hayek, S. S. et al. Soluble urokinase receptor and chronic kidney disease. N. Engl. J. Med. 373, 1916–1925 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.G. is a consultant for Alexion. S.E.Q. owns stock in and is a director of Mannin Research.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Gallon, L., Quaggin, S. A suPAR kidney connection found in the bone marrow. Nat Rev Nephrol 13, 263–264 (2017). https://doi.org/10.1038/nrneph.2017.29
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.29
This article is cited by
-
Development of membranoproliferative glomerulonephritis-like glomerulopathy in a patient with neutrophilia resulting from endogenous granulocyte-colony stimulating factor overproduction: a case report
BMC Nephrology (2018)
-
Experimental concerns regarding suPAR-related proteinuria
Nature Reviews Nephrology (2017)
-
SuPAR and FSGS: is the jury still out?
Nature Reviews Nephrology (2017)
